UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells

Advances in Hematology, 2013, Vol.2013 (2013), p.126-133

2013

Volltextzugriff (PDF)

No recovery of T-cell receptor excision circles (TRECs) after non-myeloablative allogeneic hematopoietic stem cell transplantation is correlated with the onset of GvHD

Journal of applied genetics, 2007-01, Vol.48 (4), p.397-404

2007

Volltextzugriff (PDF)

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Advances in Hematology, 2010, Vol.2010 (2010), p.50-60

2010

Volltextzugriff (PDF)

Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis

Cancer research (Chicago, Ill.), 1999-09, Vol.59 (17), p.4233-4236

1999

Volltextzugriff (PDF)

Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8027-8027

2020

Volltextzugriff (PDF)

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7066-TPS7066

2017

Volltextzugriff (PDF)

Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection

Biological trace element research, 1997-01, Vol.56 (1), p.31-41

1997

Volltextzugriff (PDF)

Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease

AIDS research and human retroviruses, 2000-09, Vol.16 (13), p.1215-1221

2000

Volltextzugriff (PDF)

Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7513-7513

2018

Volltextzugriff (PDF)

The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS7582-TPS7582

2018

Volltextzugriff (PDF)

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e18079-e18079

2015

Volltextzugriff (PDF)

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7092-7092

2015

Volltextzugriff (PDF)

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7011-7011

2014

Volltextzugriff (PDF)

Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7004-7004

2013

Volltextzugriff (PDF)

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

The New England journal of medicine, 2019-06, Vol.380 (23), p.2225-2236

2019

Volltextzugriff (PDF)

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Cytometry. Part B, Clinical cytometry, 2018-01, Vol.94 (1), p.121-128

2018

Volltextzugriff (PDF)

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

The New England journal of medicine, 2014-03, Vol.370 (12), p.1101-1110

2014

Volltextzugriff (PDF)

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3209-3216

2012

Volltextzugriff (PDF)

Thrombopoietin mimetics for patients with myelodysplastic syndromes

Cochrane database of systematic reviews, 2017-09, Vol.9 (9), p.CD009883

2017

Volltextzugriff (PDF)

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

The lancet oncology, 2018-09, Vol.19 (9), p.1215-1228

2018

Volltextzugriff (PDF)

A novel hierarchical prognostic model of AML solely based on molecular mutations

Blood, 2012-10, Vol.120 (15), p.2963-2972

2012

Volltextzugriff (PDF)

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Blood, 2012-09, Vol.120 (10), p.2032-2041

2012

Volltextzugriff (PDF)

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

American journal of hematology, 2024-06, Vol.99 (6), p.1192-1195

2024

Volltextzugriff (PDF)

1 – 25 von 336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(302)
Mit Volltextzugriff
(286)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(182)
Life Sciences & Biomedicine
(159)
Humans
(141)
Male
(81)
Female
(73)
Middle Aged
(71)
Hematology
(68)
Aged
(63)
Biological And Medical Sciences
(56)
Medical Sciences
(51)
Oncology
(47)
Adult
(46)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(27)
Aged, 80 And Over
(26)
Prognosis
(25)
Leukemia
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Treatment Outcome
(23)
Case-Control Studies
(21)
Chronic Lymphocytic Leukemia
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells

No recovery of T-cell receptor excision circles (TRECs) after non-myeloablative allogeneic hematopoietic stem cell transplantation is correlated with the onset of GvHD

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis

Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection

Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease

Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia

The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial

Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Thrombopoietin mimetics for patients with myelodysplastic syndromes

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

A novel hierarchical prognostic model of AML solely based on molecular mutations

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

Suchergebnisse filtern